[{"id":"a0d0e389-447c-4476-ad0f-b6fe4f94829c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06429397","created_at":"2024-05-28T20:34:54.364Z","updated_at":"2024-07-02T16:35:00.861Z","phase":"Phase 2","brief_title":"First-line Anlotinib Combined With Penpulimab for Advanced Pheochromocytoma: A Single-arm, Multicenter, Prospective Phase II Study","source_id_and_acronym":"NCT06429397","lead_sponsor":"Sun Yat-sen University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Anniko (penpulimab-kcqx)"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 05/15/2024","start_date":" 05/15/2024","primary_txt":" Primary completion: 05/20/2024","primary_completion_date":" 05/20/2024","study_txt":" Completion: 05/28/2026","study_completion_date":" 05/28/2026","last_update_posted":"2024-05-27"},{"id":"adafb65f-1db8-411e-b7ca-64286135dd62","acronym":"","url":"https://clinicaltrials.gov/study/NCT03866993","created_at":"2021-01-18T19:04:18.154Z","updated_at":"2024-07-02T16:35:11.513Z","phase":"Phase 3","brief_title":"A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03866993","lead_sponsor":"Akeso","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Anniko (penpulimab-kcqx)"],"overall_status":"Completed","enrollment":" Enrollment 350","initiation":"Initiation: 12/20/2018","start_date":" 12/20/2018","primary_txt":" Primary completion: 10/08/2020","primary_completion_date":" 10/08/2020","study_txt":" Completion: 01/14/2022","study_completion_date":" 01/14/2022","last_update_posted":"2024-04-03"},{"id":"d7c1dd23-b592-49e2-9ffb-7f723f3c6b6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06010901","created_at":"2023-08-25T15:08:21.904Z","updated_at":"2024-07-02T16:35:22.516Z","phase":"Phase 1","brief_title":"A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.","source_id_and_acronym":"NCT06010901","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Anniko (penpulimab-kcqx) • TQB2618"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 01/13/2024","start_date":" 01/13/2024","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-01-23"},{"id":"6d17eabe-16d8-4590-8d9b-337ef0855fd7","acronym":"ZL-IRIAN","url":"https://clinicaltrials.gov/study/NCT05229003","created_at":"2022-02-09T17:52:48.648Z","updated_at":"2024-07-02T16:35:27.176Z","phase":"Phase 2","brief_title":"Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC","source_id_and_acronym":"NCT05229003 - ZL-IRIAN","lead_sponsor":"Fudan University","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" BRAF wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • irinotecan • Anniko (penpulimab-kcqx)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 03/09/2022","start_date":" 03/09/2022","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2023-12-05"},{"id":"b5f4406c-d75e-438c-a67b-80bd41e9ae91","acronym":"","url":"https://clinicaltrials.gov/study/NCT05260671","created_at":"2022-03-02T17:52:29.534Z","updated_at":"2024-07-02T16:35:32.847Z","phase":"Phase 2","brief_title":"Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN","source_id_and_acronym":"NCT05260671","lead_sponsor":"Eye \u0026 ENT Hospital of Fudan University","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Anniko (penpulimab-kcqx)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 01/25/2022","start_date":" 01/25/2022","primary_txt":" Primary completion: 12/25/2024","primary_completion_date":" 12/25/2024","study_txt":" Completion: 12/25/2026","study_completion_date":" 12/25/2026","last_update_posted":"2023-10-18"},{"id":"288c4f76-3df6-413f-bc79-bddb29118d57","acronym":"","url":"https://clinicaltrials.gov/study/NCT06048315","created_at":"2023-09-21T14:10:48.638Z","updated_at":"2024-07-02T16:35:36.259Z","phase":"Phase 3","brief_title":"A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody","source_id_and_acronym":"NCT06048315","lead_sponsor":"Degan Lu","biomarkers":" EGFR • BRAF","pipe":" | ","alterations":" EGFR mutation • EGFR positive","tags":["EGFR • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Focus V (anlotinib) • Anniko (penpulimab-kcqx)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-09-21"},{"id":"6bdce55b-ef4a-469e-8114-7ca9780e7472","acronym":"","url":"https://clinicaltrials.gov/study/NCT05834543","created_at":"2023-04-28T15:04:40.318Z","updated_at":"2024-07-02T16:35:49.345Z","phase":"Phase 1/2","brief_title":"Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma","source_id_and_acronym":"NCT05834543","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • Anniko (penpulimab-kcqx) • TQB2618"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-04-28"},{"id":"394b8ab4-da79-4d31-92c2-e88c738add9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05400876","created_at":"2022-06-02T16:58:53.336Z","updated_at":"2024-07-02T16:35:55.602Z","phase":"Phase 1/2","brief_title":"To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma","source_id_and_acronym":"NCT05400876","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" PD-L1 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Anniko (penpulimab-kcqx) • TQB2618"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 06/09/2022","start_date":" 06/09/2022","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 10/01/2023","study_completion_date":" 10/01/2023","last_update_posted":"2023-02-14"},{"id":"faea9c00-c10c-458b-91fa-796e1bdeacd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05726175","created_at":"2023-02-13T15:01:00.421Z","updated_at":"2024-07-02T16:35:55.775Z","phase":"Phase 2","brief_title":"Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer","source_id_and_acronym":"NCT05726175","lead_sponsor":"West China Hospital","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin) • Anniko (penpulimab-kcqx)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2023-02-13"},{"id":"4ea09284-413f-4345-8aca-624a8b79d302","acronym":"N-PRC","url":"https://clinicaltrials.gov/study/NCT05576480","created_at":"2022-10-12T13:56:51.512Z","updated_at":"2024-07-02T16:36:02.629Z","phase":"Phase 2","brief_title":"SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT05576480 - N-PRC","lead_sponsor":"Ruijin Hospital","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • Anniko (penpulimab-kcqx)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2022-10-12"},{"id":"1eb24167-be44-47fd-b0d3-d2a6d201e146","acronym":"ANSWER","url":"https://clinicaltrials.gov/study/NCT05214222","created_at":"2022-01-29T18:05:22.899Z","updated_at":"2024-07-02T16:36:03.238Z","phase":"Phase 2","brief_title":"Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma","source_id_and_acronym":"NCT05214222 - ANSWER","lead_sponsor":"Nanfang Hospital of Southern Medical University","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Focus V (anlotinib) • albumin-bound paclitaxel • Anniko (penpulimab-kcqx)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 09/02/2022","start_date":" 09/02/2022","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2022-09-29"},{"id":"91d56898-90ad-41f7-a76c-02e667ac22e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05488353","created_at":"2022-08-04T14:55:36.612Z","updated_at":"2024-07-02T16:36:06.050Z","phase":"Phase 4","brief_title":"A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma","source_id_and_acronym":"NCT05488353","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Aidixi (disitamab vedotin) • Anniko (penpulimab-kcqx)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 09/01/2022","start_date":" 09/01/2022","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2022-08-04"},{"id":"c05df993-ee54-4872-9524-25f9ad2aebd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05485350","created_at":"2022-08-03T15:54:55.023Z","updated_at":"2024-07-02T16:36:06.210Z","phase":"Phase 2","brief_title":"Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05485350","lead_sponsor":"Peking University Third Hospital","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK positive • EGFR positive","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Anniko (penpulimab-kcqx)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 09/12/2022","start_date":" 09/12/2022","primary_txt":" Primary completion: 09/21/2023","primary_completion_date":" 09/21/2023","study_txt":" Completion: 10/15/2024","study_completion_date":" 10/15/2024","last_update_posted":"2022-08-03"},{"id":"04a9b159-8750-41fc-9f7f-22b4395ff6ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT05460481","created_at":"2022-07-15T16:05:34.868Z","updated_at":"2024-07-02T16:36:07.086Z","phase":"Phase 2","brief_title":"Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors","source_id_and_acronym":"NCT05460481","lead_sponsor":"Hunan Cancer Hospital","biomarkers":" EGFR • ROS1","pipe":" | ","alterations":" ALK wild-type • ROS1 wild-type","tags":["EGFR • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK wild-type • ROS1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Anniko (penpulimab-kcqx)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 06/12/2022","start_date":" 06/12/2022","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-07-20"},{"id":"aa5d805e-253c-4800-bfa8-f44091a461fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05244993","created_at":"2022-02-17T18:22:22.616Z","updated_at":"2024-07-02T16:36:07.491Z","phase":"Phase 2","brief_title":"AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer","source_id_and_acronym":"NCT05244993","lead_sponsor":"Liaoning Tumor Hospital \u0026 Institute","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • albumin-bound paclitaxel • Anniko (penpulimab-kcqx)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2022-07-12"},{"id":"a85a2db2-5a46-4f3f-b9bc-426397471b82","acronym":"pcwaintrl","url":"https://clinicaltrials.gov/study/NCT05387109","created_at":"2022-05-24T12:54:18.949Z","updated_at":"2024-07-02T16:36:09.982Z","phase":"Phase 4","brief_title":"Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05387109 - pcwaintrl","lead_sponsor":"Tang-Du Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Anniko (penpulimab-kcqx)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 04/20/2023","primary_completion_date":" 04/20/2023","study_txt":" Completion: 04/20/2024","study_completion_date":" 04/20/2024","last_update_posted":"2022-05-24"},{"id":"06d8aeb6-1454-41de-83b4-e1f8ba6216e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05313906","created_at":"2022-04-06T13:52:55.993Z","updated_at":"2024-07-02T16:36:13.889Z","phase":"Phase 2","brief_title":"RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer","source_id_and_acronym":"NCT05313906","lead_sponsor":"Henan Cancer Hospital","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Aidixi (disitamab vedotin) • Anniko (penpulimab-kcqx)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/07/2022","start_date":" 05/07/2022","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2022-04-06"},{"id":"940330f9-15fc-45e6-89b1-cf8c69b54ba6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05186558","created_at":"2022-01-11T15:56:04.506Z","updated_at":"2024-07-02T16:36:15.975Z","phase":"Phase 2","brief_title":"Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL","source_id_and_acronym":"NCT05186558","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • lenalidomide • oxaliplatin • Anniko (penpulimab-kcqx)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 05/15/2022","start_date":" 05/15/2022","primary_txt":" Primary completion: 01/15/2024","primary_completion_date":" 01/15/2024","study_txt":" Completion: 02/15/2026","study_completion_date":" 02/15/2026","last_update_posted":"2022-03-07"},{"id":"215eb3c9-067f-4639-92b9-5c3efcbdd686","acronym":"","url":"https://clinicaltrials.gov/study/NCT05137171","created_at":"2021-11-30T12:53:34.638Z","updated_at":"2024-07-02T16:36:20.074Z","phase":"Phase 2","brief_title":"AK105 Combined With Anlotinib in Patients With Cervical Cancer","source_id_and_acronym":"NCT05137171","lead_sponsor":"The First Affiliated Hospital of Zhengzhou University","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Anniko (penpulimab-kcqx)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2021-11-30"},{"id":"c9c5cc45-748a-4a71-a608-05bebad3c182","acronym":"","url":"https://clinicaltrials.gov/study/NCT05068206","created_at":"2021-10-05T20:00:18.001Z","updated_at":"2024-07-02T16:36:22.729Z","phase":"Phase 2","brief_title":"A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx","source_id_and_acronym":"NCT05068206","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS expression","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Focus V (anlotinib) • capecitabine • oxaliplatin • Anniko (penpulimab-kcqx)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 10/08/2021","start_date":" 10/08/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2021-10-20"},{"id":"73edd220-4c6b-475f-8d64-3dc9ca28f23d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05033587","created_at":"2021-09-05T16:55:45.687Z","updated_at":"2024-07-02T16:36:24.896Z","phase":"Phase 2","brief_title":"Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.","source_id_and_acronym":"NCT05033587","lead_sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Anniko (penpulimab-kcqx)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 09/01/2021","start_date":" 09/01/2021","primary_txt":" Primary completion: 05/01/2023","primary_completion_date":" 05/01/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2021-09-03"},{"id":"ac5e70dc-6ce1-4496-9759-7522e5e0fe40","acronym":"ALTER-L043","url":"https://clinicaltrials.gov/study/NCT04846634","created_at":"2021-04-15T12:53:10.793Z","updated_at":"2024-07-02T16:36:31.907Z","phase":"Phase 2","brief_title":"Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)","source_id_and_acronym":"NCT04846634 - ALTER-L043","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" ALK mutation • ROS1 fusion","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK mutation • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • Focus V (anlotinib) • pemetrexed • Anniko (penpulimab-kcqx)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2021-04-15"},{"id":"c3d8bce4-71bd-4bf0-93da-6b3e93e57f3a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04291248","created_at":"2021-01-18T20:49:32.356Z","updated_at":"2024-07-02T16:36:49.359Z","phase":"Phase 2","brief_title":"A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor","source_id_and_acronym":"NCT04291248","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • Anniko (penpulimab-kcqx)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 138","initiation":"Initiation: 03/01/2020","start_date":" 03/01/2020","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-03-02"}]